Prospect of Stem Cell Therapy and Regenerative Medicine in Osteoporosis
»
Prospect of Stem Cell Therapy and Regenerative Medicine in Osteoporosis
The field of cell therapy and regenerative medicine could hold the promise of restoring normal tissue structure and function. In addition, the main target of stem cell-based therapies is the chronic disease and disability for life without certain drugs such as osteoporosis.
Osteoporosis as one of the important causes of morbidity in older men and post-menopausal women is characterized by reduced quantity of bone or atrophy of bone tissue that leads to increased risk of osteoporotic fractures. A common treatment method for osteoporosis can only prevent the loss of bone mass and bone recover partially.
However, stem cell-based therapy is considered as a new approach to the regeneration of bone tissue. Here, the mesenchymal stem cells as an important candidate for the purpose of regenerative medicine especially the regeneration of bone is a common type of most of the cells with anti-inflammatory potential of the immune-privileged, and worry less ethical than other types of stem cells are investigated in osteoporosis. Based on the findings, the effectiveness of the mesenchymal stem cells close to a large extent dependent on their secretory function. Indeed, they could be involved in the formation of normal bone remodeling through the initiation of a specific molecular signaling pathway.
Thus, the purpose here is to review the effect of stem cell-based therapies in osteoporosis. Special edition of “Stem Cells and Regenerative Medicine” enthusiastic released by the editorial board of the European Journal of histochemistry in 2020. The fusion of these two topics reflect the expectations and potential that advances in regenerative medicine will be the promising results from basic and translational research collected in this special issue , This issue is dedicated to identifying priorities in stem cell biology and catch the latest thinking in stem cell-based regenerative medicine.
the additional role of mesenchymal stem cells as regenerative medicine army to weaken the inflammatory process of severe acute respiratory tract infection caused by COVID-19
Acute respiratory infections as one of the most common problems of the health system can also be considered as an important reason for the worldwide morbidity and mortality from infectious diseases. Coronavirus is a well-known group of respiratory viruses that can cause acute respiratory infections.
In current conditions, the new coronavirus cited 2019 as the worldwide agent for the respiratory system problems. According to the investigation, people with old age and the underlying disease are at higher risk than 2019 new coronavirus infection. Indeed, they might indicate a severe form of the disease (severe acute respiratory infection).
Based on the promising role of cell therapy and regenerative medicine approaches in the treatment of life-threatening diseases, it seems to apply a cell-based approach can also be a strategy hopes to raise the subject with severe acute respiratory tract infection caused by a new coronavirus 2019. Here, because of the amazing effects of mesenchymal stem cells in the treatment of various diseases, this review focuses on the additional role of mesenchymal stem cells to decrease the acute inflammatory process of respiratory infections caused by respiratory infections Novel coronavirus.
Description: This mAb reacts only with the intact-HCG and not with either free alpha- or free beta-chain of HCG. HCG is a glycoprotein and is composed of two non-identical, non-covalently linked polypeptide chains designated as the alpha and beta subunits. The alpha subunit is identical to that of thyroid stimulating hormone (TSH), follicle stimulating hormone (FSH), and luteinizing hormone (LH). HCG is secreted in large quantities by normal trophoblasts. It is present only in trace amounts in non-pregnant urine and sera but rises sharply during pregnancy. HCG mAb detects cells and tumors of trophoblastic origin such as choriocarcinoma. Large cell carcinoma and adenocarcinoma of the lung demonstrate anti-hCG positivity in 90% and 60% of cases respectively. 20% of lung squamous cell carcinomas are positive. HCG expression by non-trophoblastic tumors may indicate aggressive behavior.
Description: This mAb reacts only with the intact-HCG and not with either free alpha- or free beta-chain of HCG. HCG is a glycoprotein and is composed of two non-identical, non-covalently linked polypeptide chains designated as the alpha and beta subunits. The alpha subunit is identical to that of thyroid stimulating hormone (TSH), follicle stimulating hormone (FSH), and luteinizing hormone (LH). HCG is secreted in large quantities by normal trophoblasts. It is present only in trace amounts in non-pregnant urine and sera but rises sharply during pregnancy. HCG mAb detects cells and tumors of trophoblastic origin such as choriocarcinoma. Large cell carcinoma and adenocarcinoma of the lung demonstrate anti-hCG positivity in 90% and 60% of cases respectively. 20% of lung squamous cell carcinomas are positive. HCG expression by non-trophoblastic tumors may indicate aggressive behavior.
Description: This mAb reacts only with the intact-HCG and not with either free alpha- or free beta-chain of HCG. HCG is a glycoprotein and is composed of two non-identical, non-covalently linked polypeptide chains designated as the alpha and beta subunits. The alpha subunit is identical to that of thyroid stimulating hormone (TSH), follicle stimulating hormone (FSH), and luteinizing hormone (LH). HCG is secreted in large quantities by normal trophoblasts. It is present only in trace amounts in non-pregnant urine and sera but rises sharply during pregnancy. HCG mAb detects cells and tumors of trophoblastic origin such as choriocarcinoma. Large cell carcinoma and adenocarcinoma of the lung demonstrate anti-hCG positivity in 90% and 60% of cases respectively. 20% of lung squamous cell carcinomas are positive. HCG expression by non-trophoblastic tumors may indicate aggressive behavior.
Description: This assay employs the competitive inhibition enzyme immunoassay technique. The microtiter plate provided in this kit has been pre-coated with Human Holo TC protein. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Human Holo TC. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Human Holo TC in the samples is then determined by comparing the OD of the samples to the standard curve.
Description: This assay employs the competitive inhibition enzyme immunoassay technique. The microtiter plate provided in this kit has been pre-coated with Human Holo TC protein. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Human Holo TC. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Human Holo TC in the samples is then determined by comparing the OD of the samples to the standard curve.
Description: Recombinant Human Holo Lactoferrin produced in Plant is a glycosylated mature polypeptide sequence without signal 1-19 peptide, chain 20-712 AA. Having an approximate molecular mass of 77-80 kDa.;The Human Holo Lactotransferrin is purified by proprietary chromatographic techniques.
Acute 2019 as one of the problems of the most public health system can also be considered as an important reason for the worldwide morbidity and mortality from infectious diseases. Coronavirus is a well-known group of respiratory viruses that can cause acute respiratory infections. In current conditions, the new coronavirus cited 2019 as the worldwide agent for the respiratory system problems.